pmid,title,journal,year,drug,disease
40704637,Delayed diagnosis of STAT1 gain-of-function variant in a patient with multiple endocrine autoimmunity and recurrent fungal infections.,"Endocrinology, diabetes & metabolism case reports",2025,Ruxolitinib,Type 1 Diabetes
39823736,Janus kinase inhibition prevents autoimmune diabetes in LEW.1WR1 rats.,Journal of autoimmunity,2025,Ruxolitinib,Type 1 Diabetes
25905375,Autoimmune Polyglandular Syndromes.,,2000,Ruxolitinib,Type 1 Diabetes
37854597,"Deucravacitinib, a tyrosine kinase 2 pseudokinase inhibitor, protects human EndoC-betaH1 beta-cells against proinflammatory insults.",Frontiers in immunology,2023,Ruxolitinib,Type 1 Diabetes
33027576,"STAT1 Gain of Function, Type 1 Diabetes, and Reversal with JAK Inhibition.",The New England journal of medicine,2020,Ruxolitinib,Type 1 Diabetes
32944850,Ruxolitinib Controls Lymphoproliferation and Diabetes in a STAT3-GOF Patient.,Journal of clinical immunology,2020,Ruxolitinib,Type 1 Diabetes
30269996,PDL1 is expressed in the islets of people with type 1 diabetes and is up-regulated by interferons-alpha and-gamma via IRF1 induction.,EBioMedicine,2018,Ruxolitinib,Type 1 Diabetes
29305625,IFN-alpha induces a preferential long-lasting expression of MHC class I in human pancreatic beta cells.,Diabetologia,2018,Ruxolitinib,Type 1 Diabetes
